Clinical trial
Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer
NCT00388687 · Medical University of Vienna, Other · Unknown status
Key facts
| NCT number | NCT00388687 |
|---|---|
| Title | Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer |
| Official title | Hypoxia Imaging With the Novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic Impact in Cervical Cancer |
| Lead sponsor | Medical University of Vienna, Other |
| Status | Unknown status |
| Study type | Observational |
| Conditions | Uterine Cervical Neoplasms |
| Intervention type | Drug |
| Interventions | 18F Fluoroazomycin Arabinoside (FAZA) |
| Enrollment | 25 |
| Start date | Jul 1, 2006 |
| Completion | Jul 1, 2007 |
| First posted | Oct 17, 2006 |
| Last update posted | Oct 17, 2006 |
| Countries | Austria |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: